secwatch / observer
8-K filed September 10, 2025, 7:59 PM ET ticker LSAK CIK 0001041514
other material confidence high sentiment negative materiality 0.65

Lesaka Technologies restates Q1-Q3 FY2025 financials due to revenue classification error

LESAKA TECHNOLOGIES INC

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001062993-25-015498
form_type
8-K
ticker
LSAK
cik
0001041514
company_name
LESAKA TECHNOLOGIES INC
filed_at
2025-09-10T23:59:59+00:00
discovered_at
2026-05-14T18:02:43.179861+00:00
generated_at
2026-05-17T06:57:16.652006+00:00
sec_items
["4.02", "9.01"]
event_type
other_material
sentiment
negative
materiality_score
0.65
calibrated_materiality_score
0.65
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001062993-25-015498
json_url
https://secwatch.observer/filing/0001062993-25-015498.json
markdown_url
https://secwatch.observer/filing/0001062993-25-015498.md
text_url
https://secwatch.observer/filing/0001062993-25-015498.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1041514/000106299325015498/0001062993-25-015498-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1041514/000106299325015498/form8k.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null

Source-grounded claims

e2970a93f1da71e9afd74b88378cfb8873a125d9

LESAKA TECHNOLOGIES INC reported that prior financial statements should not be relied upon.

should be restated, and that such unaudited condensed financial statements should no longer be relied upon

SEC 8-K Item 4.01/4.02 confidence 0.9 SEC evidence

Comparable filings

IVF

INVO Fertility restates 2025 Q1-Q3 financials; non-reliance due to accounting errors

INVO Fertility, Inc. June 2, 2026, 8:30 AM ET other_material Items 4.02, 9.01

same fact type: auditor_change same SEC item: 4.02, 9.01 same event type: other_material similar materiality

This filing

should be restated, and that such unaudited condensed financial statements should no longer be relied upon

Comparable filing

On June 1, 2026, the audit committee of the Company, after considering the recommendations of management, concluded that the Company’s previously issued unaudited consolidated financial statements contained within its (i) Quarterly Report on Form 10-Q as of March 31, 2025 and for the three months then ended, filed with the Securities and Exchange Commission (“SEC”) on May 20, 2025, (ii) Quarterly Report on Form 10-Q as of June 30, 2025 and for the three and six months then ended, filed with the SEC on August 14, 2025, and (iii) Quarterly Report on Form 10-Q as of September 30, 2025 and for the three and nine months then ended, filed with the SEC on November 17, 2025 should no longer be relied due the 2025 Financial Statement Errors.

Filing page SEC filing

GWLL

Goldenwell Biotech to restate three quarterly reports over $9,840 legal fee timing errors

GOLDENWELL BIOTECH, INC. May 26, 2026, 8:17 PM ET other_material Items 4.02, 9.01

same fact type: auditor_change same SEC item: 4.02, 9.01 same event type: other_material similar materiality

This filing

should be restated, and that such unaudited condensed financial statements should no longer be relied upon

Comparable filing

the Company’s independent registered public accounting firm, Michael Gillsepie & Associates, PLLC (“Gillespie & Associates”), notified the Company that the Company did not follow US GAAP because an invoice dated September 23, 2025, from the Company’s legal counsel in the amount of $9,840 to the Company, which covered legal services rendered to the Company between May 21, 2024 and September 23, 2025, should have been recorded in the fiscal quarters when services were performed

Filing page SEC filing

NMTC

NeuroOne restates Q1 FY2026 results due to revenue recognition error; reaffirms FY2026 guidance

NEUROONE MEDICAL TECHNOLOGIES Corp May 22, 2026, 4:30 PM ET other_material Items 4.02, 7.01, 9.01

same fact type: auditor_change same SEC item: 4.02, 9.01 same event type: other_material similar materiality

This filing

should be restated, and that such unaudited condensed financial statements should no longer be relied upon

Comparable filing

On May 21, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of NeuroOne Medical Technologies Corporation (the “Company”), after discussion with management, determined that the Company’s previously issued interim financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed on May 12, 2026 (the “Previous Filing”), should no longer be relied upon and should be restated because of accounting errors relating to revenue recognition.

Filing page SEC filing

CGC

Canopy Growth restates FY2024-2025 financials due to warrant classification error; Q4/FY2026 results delayed to June 15

Canopy Growth Corp May 15, 2026, 5:06 PM ET other_material Items 4.02, 7.01, 9.01

same fact type: auditor_change same SEC item: 4.02, 9.01 same event type: other_material similar materiality

This filing

should be restated, and that such unaudited condensed financial statements should no longer be relied upon

Comparable filing

the audit committee of the board of directors of the Company (the “Audit Committee”) was made aware of and, after discussion with senior management of the Company, concluded that the Company’s previously issued (i) audited consolidated financial statements for the fiscal year ended March 31, 2024, included in the Company’s Annual Report on Form 10-K for such fiscal year (the “2024 10-K”), (ii) audited consolidated financial statements for the fiscal year ended March 31, 2025, included in the Company’s Annual Report on Form 10-K for such fiscal year (the “2025 10-K”) and (iii) unaudited consolidated financial statements for the quarterly periods ended September 30, 2023, December 31, 2023, June 30, 2024, September 30, 2024, December 31, 2024, June 30, 2025, September 30, 2025, and December 31, 2025, included in the Company’s Quarterly Reports on Form 10-Q for such quarterly periods (collectively, the “Prior Financial Statements”), should no longer be relied upon

Filing page SEC filing

PREAXIA HEALTH CARE PAYMENT SYSTEMS INC.

PreAxia restates Aug 31, 2025 financials; stock award errors, material weakness

PREAXIA HEALTH CARE PAYMENT SYSTEMS INC. April 21, 2026, 7:59 PM ET other_material Items 4.02, 9.01

same fact type: auditor_change same SEC item: 4.02, 9.01 same event type: other_material similar materiality

This filing

should be restated, and that such unaudited condensed financial statements should no longer be relied upon

Comparable filing

On April 9, 2026, the management of PreAxia Health care Payment Systems Inc., a Nevada corporation (the “Company”), identified material errors in the previously released financial statements for the three months ended August 31, 2025 (the “Non-Reliance Period”) and concluded that such financial statements should no longer be relied upon.

Filing page SEC filing

CNTY

Century Casinos dismisses Grant Thornton, appoints EY as new auditor; cites material weaknesses

CENTURY CASINOS INC /CO/ May 28, 2026, 4:11 PM ET other_material Items 4.01, 9.01

same fact type: auditor_change same SEC item: 9.01 same event type: other_material similar materiality

This filing

should be restated, and that such unaudited condensed financial statements should no longer be relied upon

Comparable filing

(b) Engagement of Independent Registered Public Accounting Firm On May 22, 2026, the Audit Committee appointed Ernst & Young LLP (“EY”) as our independent registered public accounting firm to audit our consolidated financial statements for the fiscal year ending December 31, 2026.

Filing page SEC filing

SVCO

Silvaco dismisses Baker Tilly, appoints KPMG as independent auditor

Silvaco Group, Inc. May 27, 2026, 5:25 PM ET other_material Items 4.01, 9.01

same fact type: auditor_change same SEC item: 9.01 same event type: other_material similar materiality

This filing

should be restated, and that such unaudited condensed financial statements should no longer be relied upon

Comparable filing

on May 27, 2026, KPMG LLP (“KPMG”) was engaged as the Company’s independent registered public accounting firm

Filing page SEC filing

ALUR

Allurion Technologies dismisses Deloitte & Touche, appoints CBIZ; discloses material weaknesses

ALLURION TECHNOLOGIES, INC. May 27, 2026, 4:35 PM ET other_material Items 4.01, 9.01

same fact type: auditor_change same SEC item: 9.01 same event type: other_material similar materiality

This filing

should be restated, and that such unaudited condensed financial statements should no longer be relied upon

Comparable filing

On May 22, 2026 (the “Effective Date”), Deloitte was dismissed as our independent registered public accounting firm.

Filing page SEC filing

Source: SEC EDGAR
accession 0001062993-25-015498

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.